Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C

Cheong, Jae; Um, Soon; Seo, Yeon; Kim, Dong; Hwang, Seong; Lee, Youn; Cho, Mong; Yang, Jin; Kim, Young; Park, Young; Cho, Sung; Cheong, Jae Youn; Um, Soon Ho; Seo, Yeon Seok; Kim, Dong Joon; Hwang, Seong Gyu; Lee, Youn Jae; Yang, Jin Mo; Kim, Young Bae; Park, Young Nyun
February 2011
Digestive Diseases & Sciences;Feb2011, Vol. 56 Issue 2, p555
Academic Journal
journal article
Background/aims: The majority of non-invasive markers of liver fibrosis have been developed in patients with chronic hepatitis C. We aimed to develop a formula for predicting significant fibrosis in patients with chronic viral hepatitis and to compare the usefulness of published models derived from the data obtained from patients with chronic hepatitis C.Methods: Serum markers and the METAVIR stage of fibrosis in liver biopsy specimens were compared prospectively in patients with chronic hepatitis B and C (estimation set, 367; validation set, 159).Results: In the estimation set, multiple forward stepwise logistic regression analysis identified γ-glutamyl transpeptidase, haptoglobin, α2-macroglobulin, matrix metalloproteinase-2, and tissue inhibitor of metalloproteinase-1 as independent predictors of significant fibrosis. A formula termed the SF index was constructed with the aforementioned five variables. The areas under the receiver operating characteristic curves of the SF index for predicting significant fibrosis were 0.828, 0.776, and 0.827 in the estimation, validation, and total sets, respectively. Using cut-off scores of 2.2 and 3.3, significant fibrosis was predicted with considerable accuracy. The diagnostic performances of the SF index and the Zeng index derived from chronic hepatitis B patients were much better than indices derived from chronic hepatitis C patients, such as the APRI, Forns index, and FIB-4.Conclusions: We developed a novel formula for predicting significant fibrosis in patients with chronic viral hepatitis. Serum indices from studies in patients with chronic hepatitis C were less accurate in patients with chronic hepatitis B for predicting significant fibrosis.


Related Articles

  • Longitudinal Assessment of Histology Surrogate Markers (FibroTest–ActiTest) During Lamivudine Therapy in Patients with Chronic Hepatitis B Infection. Poynard, Thierry; Zoulim, Fabien; Ratziu, Vlad; Degos, Françoise; Imbert-Bismut, Francoise; Deny, Paul; Landais, Paul; El Hasnaoui, Abdelkader; Slama, Alain; Blin, Patrick; Thibault, Vincent; Parvaz, Parviz; Munteanu, Mona; Trepo, Christian // American Journal of Gastroenterology;Sep2005, Vol. 100 Issue 9, p1970 

    OBJECTIVES: The noninvasive serum markers, FibroTest–ActiTest (FT–AT), are an alternative to liver biopsy in patients with chronic hepatitis C and B. The aim was to use these markers in a prospective study of patients treated with lamivudine in order to assess the impact of...

  • Ultrastructure of Hepatorenal Cell Populations in Patients with HCV and HBV Infection Markers. Hepatorenal Associations. Nepomnyashchikh, G.; Bakarev, M.; Nepomnyashchikh, D.; Yudanov, A.; Kapustina, V.; Postnikova, O.; Vinogradova, E.; Rusinova, S.; Telegina, T. // Bulletin of Experimental Biology & Medicine;Dec2014, Vol. 158 Issue 2, p268 

    Hepatorenal cell populations were studied in patients with HCV and HBV infection markers and renal dysfunction. Pronounced mosaicism of ultrastructural changes in hepatocytes was associated with polymorphic cytopathic effects caused by RNA-genome hepatitis C virus and DNA-genome hepatitis B...

  • Serum Hyaluronic Acid as a Noninvasive Marker of Hepatic Fibrosis in Chronic Hepatitis B. Geramizadeh, Bita; Janfeshan, Katayoun; Saberfiroozi, Mehdi // Saudi Journal of Gastroenterology;Oct2008, Vol. 14 Issue 4, p174 

    Background/Aims: Chronic hepatitis B is a serious global health problem. Liver biopsy is currently recommended as the gold standard for the evaluation of the degree of fibrosis in patients with chronic hepatitis B. This procedure, however, is invasive and has potential complications. In this...

  • Novel biomarker candidates to predict hepatic fibrosis in hepatitis C identified by serum proteomics. Yang, Libang; Rudser, Kyle; Higgins, LeeAnn; Rosen, Hugo; Zaman, Atif; Corless, Christopher; David, Larry; Gourley, Glenn; Rudser, Kyle D; Rosen, Hugo R; Corless, Christopher L; Gourley, Glenn R // Digestive Diseases & Sciences;Nov2011, Vol. 56 Issue 11, p3305 

    Background: Liver biopsy remains the gold standard to assess hepatic fibrosis. It is desirable to predict hepatic fibrosis without the need for invasive liver biopsy. Proteomic techniques allow unbiased assessment of proteins and might be useful to identify proteins related to...

  • Comparison of non-invasive fibrosis markers and classical liver biopsy in chronic hepatitis C. Usluer, G.; Erben, N.; Aykin, N.; Dagli, O.; Aydogdu, O.; Barut, S.; Cevik, F.; Ormen, B. // European Journal of Clinical Microbiology & Infectious Diseases;Aug2012, Vol. 31 Issue 8, p1873 

    The aim of this study was to compare the results of nine non-invasive serum biomarkers with liver biopsies to predict liver fibrosis stage. HCV-RNA-positive, HCV genotype 1, treatment-naive patients with chronic HCV infections were included from 14 centers ( n = 77). The platelet count, AST/ALT...

  • Validation of Hepascore as a Predictor of Liver Fibrosis in Patients with Chronic Hepatitis C Infection. Kalantari, Hamid; Hoseini, Hannan; Babak, Anahita; Yaran, Majid // Hepatitis Research & Treatment;2011, p1 

    Introduction. Liver biopsy is an invasive determinator for hepatic fibrosis. Serum biomarkers can probably be used as an alternative to liver biopsy in assessment of the degree of fibrosis in patients with chronic Hepatitis C. Method. Eighty patients with chronic Hepatitis C were included in the...

  • Discovery of Novel Biomarker Candidates for Liver Fibrosis in Hepatitis C Patients: A Preliminary Study. Gangadharan, Bevin; Bapat, Manisha; Rossa, Jan; Antrobus, Robin; Chittenden, David; Kampa, Bettina; Barnes, Eleanor; Klenerman, Paul; Dwek, Raymond A.; Zitzmann, Nicole // PLoS ONE;Jun2012, Vol. 7 Issue 6, p1 

    Background: Liver biopsy is the reference standard for assessing liver fibrosis and no reliable non-invasive diagnostic approach is available to discriminate between the intermediate stages of fibrosis. Therefore suitable serological biomarkers of liver fibrosis are urgently needed. We used...

  • The Role of Serum Biomarkers in Predicting Fibrosis Progression in Pediatric and Adult Hepatitis C Virus Chronic Infection. Valva, Pamela; Casciato, Paola; Diaz Carrasco, Juan M.; Gadano, Adrian; Galdame, Omar; Galoppo, María Cristina; Mullen, Eduardo; De Matteo, Elena; Preciado, María Victoria // PLoS ONE;2011, Vol. 6 Issue 8, p1 

    Background/Aims: Liver biopsy represents the gold standard for damage evaluation, but noninvasive serum markers that mirror liver fibrosis progression are actual goals both in adults and especially in children. The aim was to determine specific serum markers that correlate with liver fibrosis...

  • Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link. Hernández-Bartolomé, Ángel; López-Rodríguez, Rosario; Rodríguez-Muñoz, Yolanda; Martín-Vílchez, Samuel; Borque, María Jesús; García-Buey, Luisa; González-Moreno, Leticia; Real, Yolanda; Moreno-Otero, Ricardo; Sanz-Cameno, Paloma // PLoS ONE;Jun2013, Vol. 8 Issue 6, p1 

    Aims: Accurate liver fibrosis staging is crucial for the management of chronic hepatitis C (CHC). The invasiveness and cost burden of liver biopsy have driven the search for new noninvasive biomarkers of fibrosis. Based on the link between serum angiopoietin-1 and 2 levels and CHC progression,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics